Tecan Group makes laboratory automation platforms, liquid handling systems and microplate readers that sit in pharma, diagnostics and life-science research workflows, with consumables and service adding recurring revenue on top. The case rests on the installed base and the switching costs that come with running validated assays on its instruments, which is a real moat in regulated end markets. The problem is that revenue is shrinking (down 2.7%) and operating margin of 4.8% against a 34.1% gross margin shows how much of the cost base is absorbing the drop-off in volume. Negative ROE of -9.7% and a forward P/E of 32.4 mean the market is paying for a recovery in instrument orders and margin leverage that the trailing numbers do not yet show. It is worth a deeper look if you believe capital spending by pharma and diagnostics customers is near a trough and that the consumables mix can lift margins back toward the gross line, but the current figures alone do not establish that.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | CHF 245 | first publication | CHF 251 |
| 22 Oct 2026, 14:04 CEST | Rating | Overvalued | first publication | CHF 244 |
| 22 Oct 2026, 14:04 CEST | Fair value | CHF 131 | first publication | CHF 244 |
Answered from Tecan Group AG fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| TECN.SW Tecan Group AG | CHF 245.40 | CHF 131 | 87% above | - | -9.7% | 44 | 48 |
| ICUI ICU Medical Inc. Common Stock | $166.62 | $111 | 51% above | 134.7x | 1.4% | 43 | 50 |
| ANN.AX Ansell Limited | A$46.27 | A$40 | 16% above | 21.6x | 10.5% | 67 | 75 |
| MMED MiniMed Group Inc. Common Stock | $18.34 | - | - | - | -8.7% | 43 | 54 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $19.49 | $12 | 57% above | 34.2x | 9.1% | 63 | 47 |
| MMSI Merit Medical Systems Inc. Common Stock | $93.30 | $59 | 59% above | 38.7x | 9.2% | 63 | 66 |
| TFX Teleflex Incorporated Common Stock | $136.29 | $131 | 4% above | - | -0.7% | 43 | 51 |
Where TECN.SW ranks against its sector peers on each metric.